Menu Back to 10th-DIA-China-Annual-Meeting

Overview

Join Us for the Ten Year Special Planning Anniversary at DIA China 10th Annual Meeting

Every year at May, the DIA China Annual Meeting, which includes the whole chain of drug R&D and focuses on clinical and regulatory science, has become the most important opportunities to exchange ideas and practices, expand network and display products & services in China healthcare community.

The 10th DIA China Annual Meeting from May 22-25, 2018 will bring together more than 2000 pharmaceutical R&D professionals from different continents and regions, involved at all levels of the health care product development spectrum, to discuss recent and upcoming transformational changes for China’s innovation and regulatory environments.

Special DIAmond Sessions will introduce global views into our perspective of the Chinese pharmaceutical ecosystem. Sessions will model the experience from the global DIA 2017 Annual Meeting in the US.  As the largest multidisciplinary event in DIA Asia, other highlights will include 100+ exhibit booths and a new, unique hub for R&D and emerging companies to showcase themselves in “Innovation Hub.”

Professionals involved at all levels in the regulation, discovery, development, and life cycle management of health care products, will travel from China and around the world to witness transformational changes for China’s innovation and regulatory environment, to share the view points, knowledge, new technologic progress, and cross-cutting collaboration towards patient centric biopharma innovation in China.

Featured topics

  • Special Forum at the Opening
  • Regulatory Science
  • CFDA Town Hall
  • Innovative Breakthrough in Therapy (Oncology, Cardiac, etc.)
  • Clinical Development (Operations, Site, GCP, etc.)
  • Quantitative Science
  • CMC & Generic Drugs
  • Biologics & Biosimilar Development
  • Medical Affairs
  • Safety & Pharmacovigilance
  • Patient Engagement
  • Big Data Research and Artificial Intelligence in Healthcare
  • Medical Devices, Companion Diagnostics, IVD
  • Hot Topics and Late Breaker (Rare Diseases, CV Research Network, Investment & BD, Portfolio Management, Payer, etc.)

Program Committee

  • Pei  HU
    Pei HU Director, Phase I Unit, Clinical Pharmacological Research Center
    Peking Union Medical College, China
  • Bin  Xue
    Bin Xue Director-General
    China Center for Food and Drug International Exchange, CFDA, China
  • Wendy  Yan, MD, MBA
    Wendy Yan, MD, MBA Senior Vice President, Head of Regulatory Affairs
    BeiGene (Beijing) Co., Ltd., China
  • Irene  Deng
    Irene Deng Head of Regulatory Affairs, China
    Sanofi, China
  • Jin  Cui
    Jin Cui Program Officer
    China Center for Food and Drug International Exchange , China
  • George  LIU
    George LIU Head of Early Development and Scientific Operation
    Harbour Biomed, China
  • Zhiqiang  Ning
    Zhiqiang Ning Vice President, Research & Clinical Development
    Shenzhen Chipscreen Biosciences, Ltd., China
  • Jessica  Liu
    Jessica Liu
    Tigermed, China
  • Sunny  Zhu
    Sunny Zhu Chief Medical Officer, Infectious Diseases
    Everest Medicines, China
  • Hannah  Chen, MD
    Hannah Chen, MD Director, Asia Pacific Strategy Lead
    BioResearch Quality & Compliance, Janssen, China
  • Paul  Dai, MD
    Paul Dai, MD Head of Clinical Operations
    TDC, Asia, Takeda, China
  • Reako  Ren
    Reako Ren Head of SMO Services
    WuXi Apptec., China
  • Connie  DAI
    Connie DAI
    Harbour Biomed, China
  • Hualong  Sun
    Hualong Sun General manager
    Meta Clinical Technical Co. Ltd, China
  • Charles  Yan
    Charles Yan Vice President
    Hengrui Data Science Center, China
  • Melly  Lin
    Melly Lin Senior Regulatory Manager, CMC Policy,
    Roche(China) Holding Ltd, China
  • Joe  Zhang
    Joe Zhang Former Head of Preclinical R&D
    Simcere Pharmaceutical Group, China
  • Xiangyang  Zhu
    Xiangyang Zhu CEO
    Shanghai Huaota Biopharma Co., Ltd, China
  • Li L Wang
    Li L Wang Vice President, Medical
    Eli Lilly, China
  • Xiaoling  Wang
    Xiaoling Wang Clinical Documentation
    Clinical Science Operation, Sanofi R&D China, China
  • Xue  TANG
    Xue TANG Drug Safety Unit Regional Head (DRH),
    APAC Pfizer, China
  • Dayao  ZHAO, MD, PhD
    Dayao ZHAO, MD, PhD Vice President and Lead, China Drug Development
    Pfizer, China
  • Jane Y. Cai, PhD
    Jane Y. Cai, PhD Former Managing Director
    DIA China, China
  • Tony  Guo
    Tony Guo Executive Director, Head of Biometrics China
    BeiGene, China
  • Tong  Guo
    Tong Guo Vice President and Head of Sales
    Greater China IQVIA, China
  • Amber  Wang
    Amber Wang Vice President, Regulatory Affairs & QA
    SmithNephew, China
  • Ruyi  He, MD
    Ruyi He, MD Chief Scientist
    Center for Drug Evaluation, CFDA, United States
  • Jingsong  WANG, MD
    Jingsong WANG, MD CEO
    Harbour Biomed (HBM), China
  • Shun  Lu
    Shun Lu Director, Shanghai Lung Cancer Center
    Shanghai Jiaotong University, China
  • Xianglin  Zhang
    Xianglin Zhang President
    Shenyang Pharmaceutical University, China
  • Carol  Zhu, MBA
    Carol Zhu, MBA Senior Vice President and Managing Director
    DIA China, China
  • Ron D. Fitzmartin, PhD, MBA
    Ron D. Fitzmartin, PhD, MBA Senior Advisor, Office of Strategic Programs, CDER
    FDA, United States
  • Murray M. Lumpkin, DIAFellow, MD, MSc
    Murray M. Lumpkin, DIAFellow, MD, MSc Deputy Director, Regulatory Affairs, Lead Global Regulatory Systems Initiatives
    Bill and Melinda Gates Foundation, United States
  • Kenneth A. Getz
    Kenneth A. Getz Director of Sponsored Research Programs and Associate Professor
    Center For the Study of Drug Development, Tufts University School of Medicine, United States
  • Sandra A. Milligan
    Sandra A. Milligan Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety
    Merck Research Laboratories, United States
  • Ling  Su, PhD
    Ling Su, PhD Past President, DIA Board of Directors; Professor
    Shenyang Pharmaceutical University, China
Load More